Fuji Pharma said on November 2 that it has filed an import license application in Thailand for FSN-013, a combination drug of estetrol and drospirenone, for the indication of contraception via its local unit. The submission by OLIC, a subsidiary…
To read the full story
Related Article
- Fuji Pharma Seeks Dysmenorrhea Use for Nextstellis in Thailand
October 2, 2025
BUSINESS
- Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
- Keio Spinoff Taps Nikon as CDMO, Targets 2027 Start for KP8011 Trial
February 25, 2026
- Astellas, Vir Strike Strategic Deal to Advance PSMA-Targeting TCE
February 25, 2026
- Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
- Opdivo-Yervoy Expands Label for Colorectal Cancer in South Korea
February 25, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





